

A Genetic Profile of Refractory Individuals with Major Depressive Disorder and Their Responsiveness to Transcranial Magnetic Stimulation

Nathália G. Souza-Silva^a, Eduardo S. Nicolau^a, Kate Hoy^b, Ziarih Hawi^c, Mark A. Bellgrove^c, Débora M. Miranda^{a,d}, Marco A. Romano-Silva^{a,e}, Paul B. Fitzgerald^{b,f}

^a Centro de Tecnologia em Medicina Molecular, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil

^b Monash Alfred Psychiatry Research Centre, Monash University Central Clinical School, Commercial Rd, Melbourne, Victoria, Australia

^c School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Australia

^d Departamento de Pediatria, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

^e Departamento de Saúde Mental, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

^f Epworth Healthcare, The Epworth Clinic, Camberwell, Victoria, Australia, 3004

To whom correspondence may be addressed:

Prof. Marco A. Romano-Silva

Avenida Professor Alfredo Balena, 190, sala 114. Belo Horizonte, Minas Gerais, CEP 30130-100, Brazil (e-mail to: romano-silva@ufmg.br)

ABSTRACT

Background: Major depressive disorder (MDD) is a debilitating illness characterized by the persistence of negative thoughts and emotions. Although antidepressant medications are effective, less than half of patients achieve complete remission despite multiple treatment trials. Repetitive transcranial magnetic stimulation (rTMS) has proven effective in the treatment of depression, especially for patients resistant to antidepressant medications. Remission rates when using rTMS for treatment-resistant depression (TRD) patients are between 30% and 40%. The responsiveness to pharmacotherapy and rTMS therapy may be influenced by genetic factors.

Objective: Here we aim to characterize the genetic profile of refractory individuals with MDD and their rTMS responsiveness.

Methods: We used an extreme-phenotype design (rTMS responders vs. non-responders) and conducted a genome wide association study on 48 participants and 593,260 SNPs.

Results: We identified 53 significant SNP associations. Gene-set enrichment analysis showed that significantly associated genes loaded onto synaptic plasticity regulation pathways. Among the genes found differentially expressed in rTMS responders compared to non-responders were *APP*, *GRID2* and *SPPL2A* genes.

Conclusions: Based on these findings, we suggest that the identified genes may influence of rTMS responsiveness. Furthermore, the rTMS responsiveness may be associated with several pathways and not just to the influence of a single gene. To the best of our knowledge, this is the first report on the genetic profile of rTMS response using a GWAS approach. Nevertheless, further studies are necessary to enlighten the molecular mechanism by which these genes affect response to rTMS treatment.

KEYWORDS: Major Depressive Disorder, Transcranial Magnetic Stimulation, Genome Wide Association Study, Treatment-resistant Depression

Introduction

Major depressive disorder (MDD) is characterized by the persistence of negative thoughts and emotions that disturb mood, cognition, motivation and behavior [1]. According to the World Health Organization (WHO) [2] depression is the main reason of disability worldwide, affecting around 300 million people. Depression can occur at any stage of life, from childhood until old age, with a twofold higher incidence in women compared to men [3]. Several treatment options are available for depression, such as pharmacological and non-pharmacological therapy, psychotherapy and brain stimulation techniques. However, less than half of patients with MDD achieve complete remission after a first line treatment with antidepressants [4].

Treatment-resistant depression (TRD) refers to the occurrence of an inadequate response after antidepressant treatment among patients that suffer from unipolar depressive disorder [5]. The most traditional concept of TRD is based on the non-responsiveness to at least two protocols of antidepressant therapy [6]. Among the patients who receive adequate treatment for MDD, only 30% respond to treatment and achieve remission. Of the remaining 70%, approximately 20% of the patients present an improvement in depressive symptoms, although not achieving remission, while 50% do not present any kind of response [7]. Due to the low efficacy of antidepressants after two attempts of treatment without success, new alternative therapies have been developed. The use of neurostimulation strategies are potential candidates acting as alternative or complementary therapies for neuropsychiatric disorders.

Repetitive transcranial magnetic stimulation (rTMS) has been demonstrated to be an effective depression treatment [8]. In rTMS, electromagnetic induction is used to induce focal currents in superficial brain regions and modulate cortical function [9]. Previous studies have demonstrated that low-frequency stimulation of rTMS (≤ 1 Hz) leads to cortical activity inhibition, whereas high-frequency stimulation (≥ 5 Hz) increases cortical excitability [10]. Although rTMS is an effective treatment for many patients with TRD, it is not always effective with remission rates ranging from 30% to 40% and response rate between 45% and 60% [11]. The factors contributing to rTMS responsiveness remain unclear. Although one potential source of inter-individual variability in responsiveness to

rTMS could be genetics, few studies have sought to identify a genetic basis of rTMS response [12].

The genetic basis of depression is well established through twin and family studies with heritability estimates ranging from 30% to 40%, and SNP-based heritability estimates ranging from 9% to 29% [13,14]. Risk of MDD is highly polygenic and involves many genes with small effects. This coupled with the clinical heterogeneity of MDD requires very high numbers of patients to find significant associations [15]. Genome-wide association study (GWAS) is a powerful tool for investigating the genetic risk factors of complex human disease, providing information about variants that may be associated with a trait [16,17]. GWAS has been used to map genetic loci, associated with MDD [18,19]. A recent GWAS conducted by Wray et al (16,823 MDD cases and 25,632 controls) identified 44 risk variants and significant loci associated to MDD [14]. Only hypothesis driven SNP genotyping approaches have been so far applied in studies with rTMS response, mainly focusing on BDNF [20–23] or serotonergic genes such as 5-HTTLPR [24].

In face of such knowledge, we hypothesized that inter-individual differences in genetics may influence the responsiveness of rTMS in patients with treatment resistant MDD. To explore this hypothesis we used an extreme-phenotype design in which we compared allelic variation genome-wide between rigorously defined rTMS responders and non-responders.

Materials and Methods

Participants

The study was approved by the Human Research and Ethics Committee of the Alfred Hospital. All patients had a DSM IV diagnosis of major depressive disorder applied by an experienced psychiatrist and confirmed by the Mini-International Neuropsychiatric Interview (M.I.N.I) [25]. Patients who received rTMS treatment whilst participating in one of two clinical trials [26,27] were recruited for genetic analysis. All patients received high frequency left sided 10Hz rTMS, either in a standard daily format or in a more accelerated treatment protocol (Table 01). Patients were asked to donate saliva for DNA samples. The

DNA extraction was conducted using a standard protocol as recommended by the supplier Oragene® (Kit Oragene-DNA | OG-600 prepIT-L2P). The resulting purified gDNA is ideal for microarray analysis.

A total of 99 (100%) individuals consented and provided samples for analysis. Clinical outcomes (response or non-response) were determined based on scores on the Montgomery Asberg Depression Rating Scale (MADRS). We compared MADRS scores from baseline to the end of acute treatment. We included individuals for analysis who were either clear responders to rTMS (a greater than 60% reduction on the MADRS scale – N = 29 (29.29%) or clear non-responders (below a 10% reduction on the MADRS scale – N = 19 (19.19%)). The remaining 51 (51.51%) subjects who demonstrated a reduction of between 11-59% were excluded from the analysis. These criteria were applied considering that extreme scoring patients (<10 >60) may present more representative genetic results to the allocated groups. Recently association studies have been sampling the extremes as a strategy for achieving good statistical power under sample size limitations. This strategy is based on the assumption that extreme phenotype sampling may increase power to detect causal variants [28–30].

TMS Treatment

Treatment followed the same conditions described by Fitzgerald *et al* [26,27]. In one study all patients received a 3 week course of 10 Hz stimulation applied to the left DLPFC with an extension of this course up to 6 weeks in total or switching to low frequency right sided rTMS or bilateral rTMS if not meeting partial response criteria at 3 weeks [26]. Patients in the second study received one of two treatment conditions – accelerated rTMS and standard rTMS. In the accelerated treatment, in week 1, patients were provided 3 sessions per day over 3 days. In week 2, patients were provided 3 sessions per day over 2 days and in week 3, 3 sessions in a single day were provided. In a standard treatment, 20 daily sessions provided 5 days per week over 4 weeks [27]. Both treatments provided trains of 10 Hz rTMS to the left dorsolateral prefrontal cortex (DLPFC).

Genotyping

Genotyping was performed using the Infinium PsychArray-24 BeadChip (Illumina, Inc., San Diego, CA, USA) and automated workflow according to the manufacturer's instructions. Raw data were analyzed using PLINK 1.9 [31].

Data quality control

Due to large number of marker loci tested in GWAS a rate of error or bias can be harmful. Therefore, to remove false-positive or false-negative associations, steps of quality control was performed to remove individuals or markers with high error rates. Data quality control was performed using PLINK 1.9 [31]. SNP inclusion required: call rate (GENO) > 90%, maximum individual missingness rate (MIND) > 10%, minor allele frequency (MAF) < 5% and Hardy-Weinberg Equilibrium (HWE) p-value > 10^{-6} .

Association analysis

For the analysis of association between the phenotype and the response to rTMS therapy we used the resources available in PLINK 1.9 [31]. We performed standard association analysis to compare allele frequency in both groups (responders and non-responders) with a 95% confidence interval through the following commands (--assoc), (-ci 0.95) (--adjust).

Pathways Analysis

The protein-protein interaction (PPI) network analysis of the identified hub genes was constructed using the Search Tool for the Retrieval of Interacting Genes (STRING) database (database of known and predicted protein-protein interactions) [32]. The resulting PPI network was then visualized using Cytoscape [33] software (software platform for visualizing molecular interaction networks and biological pathways that integrating these networks with annotations, gene expression profiles) (ClueGO plug-in) for the functional enrichment analysis.

Results

Since the observed clinical responses between both trials were similar, data analysis and results were presented in conjunction (Table 02). Quality control analysis on the raw genotypic data was conducted in 48 individuals and 593,260 SNPs. After application of data quality control criteria, 958 variants were removed due to missing genotype data, 310,522 SNPs were removed due to minor allele threshold and 4 people were removed due to missing genotype data. This left 281,780 SNPs and 44 subjects for the association study. In order to estimate the effective number of significant SNPs, we submitted the results to the False Discovery Rate (FDR) correction considering sample and SNP size per chromosome [34,35]. A new p value was then determined for each chromosome (Table 03). GWAS analysis using PLINK 1.9, revealed 53 significantly SNP associations, 11 of which were related to treatment response and 42 associated with non-responsiveness to treatment. Of the 53 associated SNPs, 25 were mapped to non-coding genomic regions. The remaining 28 SNPs mapped to protein coding genes; 9 SNPs mapped to described pathways (Table 04).

Protein-protein interaction network (PPI) analysis performed through the STRING database, presented no pathway association between the identified genes (Table 05). In an attempt to explore an interaction network analysis between the selected genes, we included common pharmacological target genes for depression treatment in the analysis. Among the pharmacological target genes were *BDNF*, *COMT*, *SLC6A1*, however, no significant protein-protein interaction network was identified (Figure 01).

Genes and pathway interaction networks were obtained after enrichment analysis using ClueGo, a Cytoscape plug-in. The pathways involved were: synaptic plasticity regulation pathway, containing - *APP* (precursor beta amyloid protein), *SPPL2A* (signaling GPCR - transmembrane proteins), *GRID2* (glutamatergic ionotropic receptor), *ADGRB3* brain-specific angiogenesis inhibitor), *COL9A3* (structural constituent of the extracellular matrix) genes (Figure 02).

Discussion

The results of this study reveal a number of SNPs that may be associated with the response to rTMS in treatment-resistant patients with major depressive disorder. Among the findings are genetic polymorphisms that have already been mapped to genes associated with the innate and adaptive autoimmune response, genes involved in the pathophysiology of Alzheimer's disease (AD), regulation of synaptogenesis and dendritic spine formation [36–38]. Although these genes point to a contribution to the overall phenotype, it is important to elucidate the effects of each gene on disease development. It is worth mentioning that the sum of multiple genetic and environmental factors leads to different clinical presentations and therapeutic responses in each patient.

In our study, the repetitive TMS (rTMS) protocol to the left DLPFC was performed in predict and accelerated modalities. It was possible to observe that the treatment model adopted did not interfere in the individuals' responsiveness to rTMS (Table 02). Therefore, for the genetic analysis patients from both protocols (predict and accelerated) were grouped.

Although we were not able to characterize a complete protein-protein interaction network with the SNP carrying genes, we were able to further describe their individual functionality and possible association to our disease and treatment in focus.

In the synaptic plasticity regulation pathway the significant genes found were related to the signaling of transmembrane proteins (*SPPL2A*), precursor of the beta amyloid protein (*APP*), exosomal component (*EXOSC7*), glutamatergic ionotropic receptor (*GRID2*), brain-specific angiogenesis inhibitor (*ADGRB3*), structural constituent of the extracellular matrix (*COL9A3*), lymphocyte antigen 9 (*LY9*) and forkhead box N3 (*FOXN3*) (Table 05).

Positive Response Associated Genetic Variants

Signal peptide peptidase-like 2a (*SPPL2A*) is a gene that encodes an aspartic intramembrane protease that plays an important role in the development and function of antigen presenting cells such as B-lymphocytes and dendritic cells. Regulated intramembrane proteolysis (RIP) is a process that controls communication between cells

and the extracellular environment mediated by a family of proteases, the intramembrane cleaving proteases (I-CLiPs) [39]. The founding members of this I-CLiPs family are the presenilins (PS1 and PS2), the catalytically active subunit of the γ -secretase complex [40]. *SPPL2A* has been described as an enzyme related to presenilins [39]. The prominent class of γ -secretase is an aspartyl I-CLiPs involved in the generation of the beta-amyloid (A β) peptide from the amyloid precursor protein (*APP*). In AD patients it is possible to find the presence of amyloid plaques in neural tissue, and it is believed that the accumulation of these polypeptides is involved in the development of the disease [41]. Previous studies have shown that depression is one of the most frequent comorbid psychiatric disorders in Alzheimer's disease and up to 50% of patients with AD will suffer from depression at some stage during the progression of dementia [42]. A study of Zhu *et al* [43] showed that similar environmental risk factors have been implicated in different neuropsychiatric diseases (including major depressive disorder and Alzheimer's disease), indicating the existence of common epigenetic mechanisms underlying the pathogenesis shared by different illnesses.

Negative Response Associated Genetic Variants

EXOSC7 is a gene encoding RNA exosome – exosome component 7. The RNA exosome is a ribonuclease complex composed of both structural and catalytic subunits that participate in the processing of stable RNA species [44]. Mutational changes in genes encoding RNA exosome subunits may trigger inherited tissue-specific diseases [45]. A study conducted by Di Donato *et al* [46] showed that mutations in *EXOSC2* have been linked to a novel syndrome characterized by early onset retinitis pigmentosa, progressive sensorineural hearing loss, hypothyroidism, premature aging and mild intellectual disability. Other studies reveal that mutations in *EXOSC3* have been linked to pontocerebellar hypoplasia type 1 (PCH1b), an autosomal-recessive, neurodegenerative disease characterized by significant atrophy of the pons and cerebellum, Purkinje cell abnormalities, and degeneration of spinal motor neurons [47].

Glutamate ionotropic receptor delta type subunit 2 (*GRID2*) is a gene member of the family of ionotropic glutamate receptors which are the predominant excitatory neurotransmitter receptors in the mammalian brain. Single nucleotide polymorphisms

(SNPs) in glutamate-related genes have been associated with antipsychotic response or treatment resistance. A GWAS conducted by Stevenson *et al* [48] identified two SNPs in the *GRID2* gene (rs9307122 and rs1875705) that were associated with reduced response to antipsychotic treatment according to the Brief Psychiatric Rating Scale change score. The results found by Stevenson *et al* [48] support the hypothesis that genetic variation in glutamate system genes may impact the clinical trajectory of the patients treated with antipsychotic medications, and that these may represent a broader involvement of neurodevelopmental pathways. Furthermore, the *GRID2* gene is selectively expressed in Purkinje cells in the cerebellum where they play a key role in synaptogenesis, synaptic plasticity and motor coordination. For that matter, different mutations in *GRID2* have been shown to cause cerebellar ataxia in human [49]. In a study conducted by Schwenkreis *et al* [50] proved the existence of abnormal motor cortex activation by TMS in some types of genetically defined spinocerebellar ataxia (SCA), whereas other genetic subgroups show normal responses.

Adhesion G protein-coupled receptor B3 (*ADGRB3*) also known as *BAI3* is a gene that encodes a brain-specific angiogenesis inhibitor and is thought to be a member of the secretin receptor family. This gene play a key role in the regulation of several aspects of the central nervous system, such as axon guidance, myelination and synapse formation and function [51]. *ADGRB3* SNPs has already been associated with schizophrenia, bipolar disorder and drug addiction. In a family-based study conducted by Scuderi *et al* [38] shows a correlation between a disrupting intragenic duplication involving several exons of the *ADGRB3* and intellectual disability, cerebellar atrophy and behavioral disorder. The BAI proteins are highly expressed in the brain and have been identified at postsynaptic densities in the forebrain and cerebellum. The involvement of these proteins in the development of functional neuronal networks is related to their structural characteristics. The morphology and complexity of dendritic arborization allow functional differences of neurons, and deficits in neuronal morphogenesis correlate with psychiatric disorders. Lanoue *et al* [52] presented evidence both *in vivo* and *in vitro* for a signaling pathway regulating the morphogenesis of dendrites involving *BAI3*. The authors suggest that an interaction between *BAI3* and the *ELMO1* protein (important regulator of *RAC1* RhoGTPase) is involved in this signaling.

COL9A3 is a gene that encodes one of the three alpha chains of the type IX collagen. Mutations in this gene are associated with multiple epiphyseal dysplasia type 3. Some of the brain collagen proteins are expressed by neurons, suggesting their involvement in growth regulation and axonal orientation, synaptogenesis, cell adhesion, and brain architecture development [53]. Collagen biosynthesis in the brain can be abnormal in many hereditary diseases. Much of the brain pathology associated with collagen are related to neurodevelopment. Collagen type IV is known to inhibit glial differentiation in cortical cell cultures and to be enhanced in the frontal and temporal cortex of patients with Alzheimer's disease [54,55].

Lymphocyte antigen 9 (*LY9*) belong to signaling lymphocytic activation molecule (SLAM) family of immunomodulatory receptors. According to previous studies, the activation of upstream gene regulatory pathways that modulate gene expression in immune cells may be linked to MDD [56]. Between the active pathways there are a family of transcription factors (TFs), the glucocorticoid receptor (GR), cAMP response element-binding (CREB), early growth response (EGR) family TFs, and pro-inflammatory cytokines, such as tumor necrosis factor- α (TNF- α), interleukin (IL)-1 β and IL-6 [57–60]. In a study conducted by Mellon *et al* [61] to test the theory on transcriptional control pathways that may be active in MDD, the authors found that among the main negatively regulated transcripts in MDD patients are the cell surface antigens of leukocytes (CD6, CD7, CD22 and LY9). Differential expression of these transcripts may be associated with possible changes in the distribution of leukocyte subset in MDD patients.

FOXP3 is a protein coding gene member of the forkhead/winged helix transcription factor family. Recent GWASs was conducted to analyze possible gene that are associated with suicide found significant correlation between evidence for suicidality and the gene *FOXP3* [62,63]. However, the way this gene may influence the risk of suicide is not fully elucidated.

Conclusions

In this study, we set out to test whether polymorphic profiles are associated to rTMS treatment outcome. From the findings, we may consider that the responsiveness to rTMS

may be associated to several pathways and not just to the influence of a single gene. As already reported in the literature the influence of genes such as *APP*, *GRID2*, *SPPL2A* and others on MDD (also described here), suggests that the genes found may influence the response to rTMS. However, the molecular mechanisms by which these genes may influence the response to rTMS treatment are unknown, requiring further investigation.

This study has some limitations that should be noted. The sample size used in this study was smaller than typically employed in genetic association studies and stratified (Australian patients with a diagnosis of major depression disorder refractory to pharmacological treatment). Although traditional GWAS require a vast number of genotyped individuals, this method is expensive and time-consuming. A potential solution for this is extreme phenotypic sampling. Recent studies have compared the results of extreme phenotypic sampling with large-scale samples, and showed that extreme phenotypes are effective [64]. This method allow to identify rare causal SNPs with increased efficiency. Due to heterogeneity of MDD the study with homogenous patient subgroups allows a better understanding about etiological mechanisms and thus the development of patient-specific treatment [65]. In addition, few reports have been found in the literature associating genetic profile and response to rTMS therapy in treatment-resistant depression patients [66–68]. Further replication is necessary to confirm the present findings and to further uncover the genetic profile of refractory individuals with MDD and their responsiveness to rTMS.

Acknowledgements

Funding

The study was supported by grants from the National Health and Medical Research Council (NHMRC) (1041890) and Alfred Hospital. PBF was supported by a Practitioner Fellowship grant from National Health and Medical Research Council (NHMRC) (1078567). NGSS was supported by a scholarship from CAPES-Brazil. KEH was supported by an NHMRC Fellowship (1135558). MAB was supported by a Senior Research Fellowship (level B) from the NHMRC (1154378). MARS and DMM were supported by Research Fellowships from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)-Brazil and a CAPES-PGCI grant (47/2014).

Conflict of Interest

PBF has received equipment for research from Medtronic, MagVenture A/S and Brainsway Ltd. He is on scientific advisory boards for Bionomics Ltd and LivaNova and is a founder of TMS Clinics Australia.

REFERENCES

- [1] Dean J, Keshavan M. The neurobiology of depression: An integrated view. *Asian J Psychiatr* 2017;27:101–11. <https://doi.org/10.1016/j.ajp.2017.01.025>.
- [2] World Health Organization. Depression and Other Common Mental Disorders 2017.
- [3] Akil H, Gordon J, Hen R, Javitch J, Mayberg H, McEwen B, et al. Treatment resistant depression: A multi-scale, systems biology approach. *Neurosci Biobehav Rev* 2018;84:272–88. <https://doi.org/10.1016/j.neubiorev.2017.08.019>.
- [4] Pandarakalam JP. CHALLENGES OF TREATMENT-RESISTANT DEPRESSION. *Narrat Rev © Med Nakl* 2018;30:273–84. <https://doi.org/10.24869/psyd.2018.273>.
- [5] Berlim MT, Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. *Eur Neuropsychopharmacol* 2007;17:696–707. <https://doi.org/10.1016/j.euroneuro.2007.03.009>.
- [6] Fava M. Diagnosis and definition of treatment-resistant depression. *Biol Psychiatry* 2003.
- [7] Gaynes BN, Lloyd SW, Lux L, Gartlehner G, Hansen RA, Brode S, et al. Repetitive transcranial magnetic stimulation for treatment-resistant depression: A systematic review and meta-analysis. *J Clin Psychiatry* 2014;75:477–89. <https://doi.org/10.4088/JCP.13r08815>.
- [8] Liston C, Chen AC, Zebley BD, Drysdale AT, Gordon R, Leuchter B, et al. Default mode network mechanisms of transcranial magnetic stimulation in depression. *Biol Psychiatry* 2014;76:517–26. <https://doi.org/10.1016/j.biopsych.2014.01.023>.
- [9] Hallett M. Transcranial Magnetic Stimulation: A Primer. *Neuron* 2007;55:187–99. <https://doi.org/10.1016/j.neuron.2007.06.026>.
- [10] Liu S, Sheng J, Li B, Zhang X. Recent advances in non-invasive brain stimulation for major depressive disorder. *Front Hum Neurosci* 2017;11. <https://doi.org/10.3389/fnhum.2017.00526>.
- [11] Kelly MS, Oliveira-Maia AJ, Bernstein M, Stern AP, Press DZ, Pascual-Leone A, et al. Initial response to transcranial magnetic stimulation treatment for depression predicts subsequent response. *J Neuropsychiatry Clin Neurosci* 2017;29:179–82. <https://doi.org/10.1176/appi.neuropsych.16100181>.
- [12] Raginis-Zborowska A, Cheng I, Pendleton N, Payton A, Ollier W, Michou E, et al. Genetic influences on the variability of response to repetitive transcranial magnetic stimulation in human pharyngeal motor cortex. *Neurogastroenterol Motil* 2019;31. <https://doi.org/10.1111/nmo.13612>.
- [13] Musliner KL, Mortensen PB, McGrath JJ, Suppli NP, Hougaard DM, Bybjerg-Grauholm J, et al. Association of Polygenic Liabilities for Major Depression, Bipolar Disorder, and Schizophrenia with Risk for Depression in the Danish Population. *JAMA Psychiatry* 2019;76:516–25. <https://doi.org/10.1001/jamapsychiatry.2018.4166>.
- [14] Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al.

- Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nat Genet* 2018;50:668–81.
<https://doi.org/10.1038/s41588-018-0090-3>.
- [15] Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al. Major depressive disorder. *Nat Rev Dis Prim* 2016;2. <https://doi.org/10.1038/nrdp.2016.65>.
- [16] Bush WS, Moore JH. Chapter 11: Genome-Wide Association Studies. *PLoS Comput Biol* 2012;8. <https://doi.org/10.1371/journal.pcbi.1002822>.
- [17] Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. *Nat Rev Genet* 2018;19:581–90. <https://doi.org/10.1038/s41576-018-0018-x>.
- [18] Koshimizu H, Nogawa S, Asano S, Ikeda M, Iwata N, Takahashi S, et al. Genome-wide association study identifies a novel locus associated with psychological distress in the Japanese population. *Transl Psychiatry* 2019;9. <https://doi.org/10.1038/s41398-019-0383-z>.
- [19] Ormel J, Hartman CA, Snieder H. The genetics of depression: successful genome-wide association studies introduce new challenges. *Transl Psychiatry* 2019;9. <https://doi.org/10.1038/s41398-019-0450-5>.
- [20] Chang WH, Bang OY, Shin Y Il, Lee A, Pascual-Leone A, Kim YH. BDNF polymorphism and differential rTMS effects on motor recovery of stroke patients. *Brain Stimul* 2014;7:553–8. <https://doi.org/10.1016/j.brs.2014.03.008>.
- [21] Cheeran B, Talelli P, Mori F, Koch G, Suppa A, Edwards M, et al. A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS. *J Physiol* 2008;586:5717–25. <https://doi.org/10.1113/jphysiol.2008.159905>.
- [22] Lu H, Zhang T, Wen M, Sun L. Impact of repetitive transcranial magnetic stimulation on post-stroke dysmnnesia and the role of BDNF val66Met SNP. *Med Sci Monit* 2015;21:761–8. <https://doi.org/10.12659/MSM.892337>.
- [23] Tulviste J, Goldberg E, Podell K, Vaht M, Harro J, Bachmann T. BDNF polymorphism in non-veridical decision making and differential effects of rTMS. *Behav Brain Res* 2019;364:177–82. <https://doi.org/10.1016/j.bbr.2019.02.027>.
- [24] Bocchio-Chiavetto L, Miniussi C, Zanardini R, Gazzoli A, Bignotti S, Specchia C, et al. 5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. *Neurosci Lett* 2008;437:130–4. <https://doi.org/10.1016/j.neulet.2008.04.005>.
- [25] Sheehan D V., Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J. Clin. Psychiatry*, vol. 59, 1998, p. 22–33.
- [26] Fitzgerald PB, Hoy KE, Elliot D, McQueen S, Wambeek LE, Daskalakis ZJ. Exploring alternative rTMS strategies in non-responders to standard high frequency left-sided treatment: A switching study. *J Affect Disord* 2018;232:79–82. <https://doi.org/10.1016/j.jad.2018.02.016>.

- [27] Fitzgerald PB, Hoy KE, Elliot D, Susan McQueen RN, Wambeek LE, Daskalakis ZJ. Accelerated repetitive transcranial magnetic stimulation in the treatment of depression. *Neuropsychopharmacology* 2018;43:1565–72. <https://doi.org/10.1038/s41386-018-0009-9>.
- [28] Barnett IJ, Lee S, Lin X. Detecting Rare Variant Effects Using Extreme Phenotype Sampling in Sequencing Association Studies. *Genet Epidemiol* 2013;37:142–51. <https://doi.org/10.1002/gepi.21699>.
- [29] Li D, Lewinger JP, Gauderman WJ, Murcray CE, Conti D. Using extreme phenotype sampling to identify the rare causal variants of quantitative traits in association studies. *Genet Epidemiol* 2011;35:790–9. <https://doi.org/10.1002/gepi.20628>.
- [30] Emond MJ, Louie T, Emerson J, Zhao W, Mathias RA, Knowles MR, et al. Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic *Pseudomonas aeruginosa* infection in cystic fibrosis. *Nat Genet* 2012;44:886–9. <https://doi.org/10.1038/ng.2344>.
- [31] Chang CC, Chow CC, Tellier LCAM, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: Rising to the challenge of larger and richer datasets. *Gigascience* 2015;4. <https://doi.org/10.1186/s13742-015-0047-8>.
- [32] Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res* 2019;47:D607–13. <https://doi.org/10.1093/nar/gky1131>.
- [33] Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A software Environment for integrated models of biomolecular interaction networks. *Genome Res* 2003;13:2498–504. <https://doi.org/10.1101/gr.1239303>.
- [34] Kaler AS, Purcell LC. Estimation of a significance threshold for genome-wide association studies. *BMC Genomics* 2019;20:618. <https://doi.org/10.1186/s12864-019-5992-7>.
- [35] Duggal P, Gillanders EM, Holmes TN, Bailey-Wilson JE. Establishing an adjusted p-value threshold to control the family-wide type 1 error in genome wide association studies. *BMC Genomics* 2008;9. <https://doi.org/10.1186/1471-2164-9-516>.
- [36] Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson P V., Bjornsson S, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. *Nature* 2012;488:96. <https://doi.org/10.1038/nature11283>.
- [37] Folts CJ, Giera S, Li T, Piao X. Adhesion G Protein-Coupled Receptors as Drug Targets for Neurological Diseases. *Trends Pharmacol Sci* 2019;40:278–93. <https://doi.org/10.1016/j.tips.2019.02.003>.
- [38] Scuderi C, Saccuzzo L, Vinci M, Castiglia L, Galesi O, Salemi M, et al. Biallelic intragenic duplication in ADGRB3 (BAI3) gene associated with intellectual disability, cerebellar atrophy, and behavioral disorder. *Eur J Hum Genet* 2019;27:594–602. <https://doi.org/10.1038/s41431-018-0321-1>.
- [39] Velcicky J, Bodendorf U, Rigollier P, Epple R, Beisner DR, Guerini D, et al. Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a

- (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In Vivo. *J Med Chem* 2018;61:865–80. <https://doi.org/10.1021/acs.jmedchem.7b01371>.
- [40] Fleck D, Voss M, Brankatschk B, Giudici C, Hampel H, Schwenk B, et al. Proteolytic processing of neuregulin 1 type III by three intramembrane-cleaving proteases. *J Biol Chem* 2016;291:318–33. <https://doi.org/10.1074/jbc.M115.697995>.
- [41] Macleod R, Hillert EK, Cameron RT, Baillie GS. The role and therapeutic targeting of α -, β - and γ -secretase in Alzheimer's disease. *Futur Sci OA* 2015;1. <https://doi.org/10.4155/fso.15.9>.
- [42] Starkstein SE, Jorge R, Mizrahi R, Robinson RG. The construct of minor and major depression in Alzheimer's disease. *Am J Psychiatry* 2005;162:2086–93. <https://doi.org/10.1176/appi.ajp.162.11.2086>.
- [43] Zhu K, Ou Yang TH, Dorie V, Zheng T, Anastassiou D. Meta-analysis of expression and methylation signatures indicates a stress-related epigenetic mechanism in multiple neuropsychiatric disorders. *Transl Psychiatry* 2019;9. <https://doi.org/10.1038/s41398-018-0358-5>.
- [44] Mitchell P, Petfalski E, Shevchenko A, Mann M, Tollervey D. The exosome: A conserved eukaryotic RNA processing complex containing multiple 3'→5' exoribonucleases. *Cell* 1997;91:457–66. [https://doi.org/10.1016/S0092-8674\(00\)80432-8](https://doi.org/10.1016/S0092-8674(00)80432-8).
- [45] Morton DJ, Kuiper EG, Jones SK, Leung SW, Corbett AH, Fasken MB. The RNA exosome and RNA exosome-linked disease. *RNA* 2018;24:127–42. <https://doi.org/10.1261/rna.064626.117>.
- [46] Di Donato N, Neuhann T, Kahlert AK, Klink B, Hackmann K, Neuhann I, et al. Mutations in EXOSC2 are associated with a novel syndrome characterised by retinitis pigmentosa, progressive hearing loss, premature ageing, short stature, mild intellectual disability and distinctive gestalt. *J Med Genet* 2016;53:419–25. <https://doi.org/10.1136/jmedgenet-2015-103511>.
- [47] Wan J, Yourshaw M, Mamsa H, Rudnik-Schöneborn S, Menezes MP, Hong JE, et al. Mutations in the RNA exosome component gene EXOSC3 cause pontocerebellar hypoplasia and spinal motor neuron degeneration. *Nat Genet* 2012;44:704–8. <https://doi.org/10.1038/ng.2254>.
- [48] Stevenson JM, Reilly JL, Harris MSH, Patel SR, Weiden PJ, Prasad KM, et al. Antipsychotic pharmacogenomics in first episode psychosis: A role for glutamate genes. *Transl Psychiatry* 2016;6. <https://doi.org/10.1038/tp.2016.10>.
- [49] Taghdiri M, Kashef A, Abbassi G, Moshtagh A, Sadatian N, Fardaei M, et al. Further delineation of the phenotype caused by a novel large homozygous deletion of GRID2 gene in an adult patient. *Clin Case Reports* 2019;7:1149–53. <https://doi.org/10.1002/ccr3.2020>.
- [50] Schwenkreis P, Tegenthoff M, Witscher K, Börnke C, Przuntek H, Malin JP, et al. Motor cortex activation by transcranial magnetic stimulation in ataxia patients depends on the genetic defect. *Brain* 2002;125:301–9. <https://doi.org/10.1093/brain/awf023>.
- [51] Hamann J, Aust G, Araç D, Engel FB, Formstone C, Fredriksson R, et al. International union of basic and clinical pharmacology. XCIV. adhesion G protein-coupled receptors.

- Pharmacol Rev 2015;67:338–67. <https://doi.org/10.1124/pr.114.009647>.
- [52] Lanoue V, Usardi A, Sigoillot SM, Talleur M, Iyer K, Mariani J, et al. The adhesion-GPCR BAI3, a gene linked to psychiatric disorders, regulates dendrite morphogenesis in neurons. *Mol Psychiatry* 2013;18:943–50. <https://doi.org/10.1038/mp.2013.46>.
- [53] Fox MA, Sanes JR, Borza DB, Eswarakumar VP, Fässler R, Hudson BG, et al. Distinct Target-Derived Signals Organize Formation, Maturation, and Maintenance of Motor Nerve Terminals. *Cell* 2007;129:179–93. <https://doi.org/10.1016/j.cell.2007.02.035>.
- [54] Lepelletier FX, Mann DMA, Robinson AC, Pinteaux E, Boutin H. Early changes in extracellular matrix in Alzheimer’s disease. *Neuropathol Appl Neurobiol* 2017;43:167–82. <https://doi.org/10.1111/nan.12295>.
- [55] Ali SA, Pappas IS, Parnavelas JG. Collagen type IV promotes the differentiation of neuronal progenitors and inhibits astroglial differentiation in cortical cell cultures. *Brain Res Dev Brain Res* 1998;110:31–8. [https://doi.org/10.1016/s0165-3806\(98\)00091-1](https://doi.org/10.1016/s0165-3806(98)00091-1).
- [56] Belzeaux R, Formisano-Tréziny C, Loundou A, Boyer L, Gabert J, Samuelian JC, et al. Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression. *J Psychiatr Res* 2010;44:1205–13. <https://doi.org/10.1016/j.jpsychires.2010.04.011>.
- [57] Weigelt K, Carvalho LA, Drexhage RC, Wijkhuijs A, Wit H de, van Beveren NJM, et al. TREM-1 and DAP12 expression in monocytes of patients with severe psychiatric disorders. EGR3, ATF3 and PU.1 as important transcription factors. *Brain Behav Immun* 2011;25:1162–9. <https://doi.org/10.1016/j.bbi.2011.03.006>.
- [58] McKee SC, Thompson CS, Sabourin LA, Hakim AM. Regulation of expression of early growth response transcription factors in rat primary cortical neurons by extracellular ATP. *Brain Res* 2006;1088:1–11. <https://doi.org/10.1016/j.brainres.2006.02.133>.
- [59] Gárate I, García-Bueno B, Madrigal JLM, Bravo L, Berrocoso E, Caso JR, et al. Origin and consequences of brain Toll-like receptor 4 pathway stimulation in an experimental model of depression. *J Neuroinflammation* 2011;8. <https://doi.org/10.1186/1742-2094-8-151>.
- [60] Pace TWW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor function: Relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. *Brain Behav Immun* 2007;21:9–19. <https://doi.org/10.1016/j.bbi.2006.08.009>.
- [61] Mellon SH, Wolkowitz OM, Schonemann MD, Epel ES, Rosser R, Burke HB, et al. Alterations in leukocyte transcriptional control pathway activity associated with major depressive disorder and antidepressant treatment. *Transl Psychiatry* 2016;6:e821. <https://doi.org/10.1038/tp.2016.79>.
- [62] Galfalvy H, Zalsman G, Huang YY, Murphy L, Rosoklija G, Dwork AJ, et al. A pilot genome wide association and gene expression array study of suicide with and without major depression. *World J Biol Psychiatry* 2013;14:574–82. <https://doi.org/10.3109/15622975.2011.597875>.
- [63] Sokolowski M, Wasserman J, Wasserman D. Polygenic associations of neurodevelopmental genes in suicide attempt. *Mol Psychiatry* 2016;21:1381–90.

<https://doi.org/10.1038/mp.2015.187>.

- [64] Wan L, Dong L, Xiao S, Han Z, Wang X, Wang Z. Genomewide association study for economic traits in the large yellow croaker with different numbers of extreme phenotypes. *J Genet* 2018;97:887–95.
- [65] Beijers L, Wardenaar KJ, van Loo HM, Schoevers RA. Data-driven biological subtypes of depression: systematic review of biological approaches to depression subtyping. *Mol Psychiatry* 2019;24:888–900. <https://doi.org/10.1038/s41380-019-0385-5>.
- [66] Fitzgerald PB, Daskalakis ZJ. The effects of repetitive transcranial magnetic stimulation in the treatment of depression. *Expert Rev Med Devices* 2011;8:85–95. <https://doi.org/10.1586/erd.10.57>.
- [67] Krstić J, Buzadžić I, Milanović SD, Ilić N V., Pajić S, Ilić T V. Low-frequency repetitive transcranial magnetic stimulation in the right prefrontal cortex combined with partial sleep deprivation in treatment-resistant depression: A randomized sham-controlled trial. *J ECT* 2014;30:325–31. <https://doi.org/10.1097/YCT.0000000000000099>.
- [68] Bonvicini C, Minelli A, Scassellati C, Bortolomasi M, Segala M, Sartori R, et al. Serotonin transporter gene polymorphisms and treatment-resistant depression. *Prog Neuro-Psychopharmacology Biol Psychiatry* 2010;34:934–9. <https://doi.org/10.1016/j.pnpbp.2010.04.020>.
- [69] Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards suite: From gene data mining to disease genome sequence analyses. *Curr Protoc Bioinforma* 2016;2016:1.30.1-1.30.33. <https://doi.org/10.1002/cpbi.5>.

Tables

Table 01. *Characteristics of participants.* Abbreviations: SSRI, Selective Serotonin Reuptake Inhibitor; MAOI, Monoamine Oxidase Inhibitor; SNRI, Serotonin-norepinephrine Reuptake Inhibitor; TCA, Tricyclic Antidepressant; RIMA, Reversible Inhibitor of Monoamine Oxidase-A; NaSSA, Noradrenergic and Specific Serotonergic Antidepressant.

Age - Mean (SD)	
Age (years)	47 (13,26)
Range (years)	19-74
Gender (%)	
Male (#)	21 (43,75)
Female (#)	27 (56,25)
Occupational status (%)	
Employed (#)	15 (31,25)
Unemployed (#)	21 (43,75)
Part-time (#)	6 (12,5)
Retired (#)	3 (6,25)
N/A (#)	3 (6,25)
Age onset (%)	
Childhood (#)	5 (10,42)
Adolescence (#)	15 (31,25)
Early adulthood (#)	16 (33,33)
Mid adulthood (#)	12 (25)
Use of antidepressant (%)	
SSRI	8 (16,66)
MAOI	3 (6,25)
SNRI	14 (29,16)
TCA	3 (6,25)
RIMA	1 (2,08)
NaSSA	1 (2,08)
Combination	7 (14,58)
None	9 (18,75)
N/A (#)	2 (4,16)

Table 02. *Response rates after treatment with rTMS.* Analysis conducted in GraphPad Prism with Chi-square Test and Fisher's exact test to show the difference between groups after treatment with rTMS (p 0.5544).

Data analyzed	Accelerated (n)	Predict (n)
Non-responders	13 (43,33%)	6 (33,33%)
Responders	17 (56,66%)	12 (66,66%)
Total	30 (100%)	18 (100%)

Table 03. New *p* value per chromosome after FDR correction.

Chr	Total SNP	New <i>p</i>-value (FDR)
1	19934	0.000106
2	20574	0.000090
3	17491	0.0000936
4	16104	0.0001141
5	15623	0.0001225
6	17610	0.0001126
7	14047	0.0001552
9	11283	0.0001893
10	12745	0.0001457
11	12742	0.0001628
12	12093	0.0001572
13	9490	0.000218
14	7895	0.0002183
15	7537	0.0002380
17	7233	0.0002747
18	7408	0.0002840
19	5896	0.0003472
21	3703	0.0004098
22	3687	0.0004761
X	6442	0.0001432

Table 04. SNPs founded. Description of significant SNPs ($p < 0.05$). A1, lower frequency allele. A2, highest frequency allele. MAF, minor allele frequency. SNV, single nucleotide variant. OR (Odds ratio) > 1 related to treatment response and OR < 1 associated to non-responsiveness treatment.

Chr	SNP	Position	Gene	Chi square	Odds Ratio	P value	A1	A2	MAF
19	rs960995	57039169	<i>ZNF471</i>	13.49	0.18	0.0002397	G	A	0.4886
7	rs17164813	11616500	<i>THSD7A</i>	16.54	0.1373	0.000047516	A	C	0.3068
15	rs8035452	51040798	<i>SPPL2A</i>	14.53	7.25	0.0001376	G	A	0.3977
18	rs595562	18449508	snv variation near genes <i>LINC01541</i> and <i>LOC107985179</i>	15.50	0.1603	0.000082719	G	A	0.3714
1	rs4648426	3773089	snv variation near genes <i>DFFB</i> and <i>CEP104</i>	14.43	0.1489	0.0001455	G	A	0.2727
3	rs12487861	160535721	<i>PPM1L</i>	18.38	16	0.000018101	A	C	0.3295
11	rs198475	61526071	<i>MYRF</i>	14.43	0.1489	0.0001455	A	G	0.2727
1	rs560681	160786670	<i>LY9</i>	14.98	0.09502	0.0001088	G	A	0.1818
1	rs11265485	160764759	<i>LY9</i>	16.98	0.08403	0.000037682	G	A	0.1932
9	rs1934115	23103266	<i>LOC107987055</i>	14.49	0.04528	0.000141	C	A	0.125
18	rs872994	73171838	<i>LOC107985177</i>	13.919	0.1769	0.0001909	A	C	0.375
22	rs5995416	37719004	<i>LOC105373024</i>	12.643	5.61	0.0003769	A	G	0.4432
19	rs2189698	57014071	<i>LOC105372471</i>	13.52	0.1839	0.0002364	C	A	0.4318
18	rs4243296	73219777	<i>LOC105372202</i>	13.92	0.1769	0.0002	G	A	0.375
6	rs6899975	138275769	<i>LINC02528</i>	14.38	0.1729	0.0001494	A	G	0.3977
17	rs1014129	49517224	<i>LINC02073</i>	17.10	0.1407	0.000035449	A	G	0.3523
13	rs626904	39984946	<i>LHFPL6</i>	14.90	0.1674	0.0001131	A	G	0.4205
2	rs17673232	144860827	<i>GTDC1</i>	19.07	0.07451	0.000012614	A	G	0.2045
4	rs11942069	94494455	<i>GRID2</i>	14.43	0.1489	0.0001455	A	G	0.2727
14	rs447347	89992265	<i>FOXN3</i>	14.79	0.1654	0.0001205	A	G	0.4773
13	rs2271926	39979675	<i>EXOSC7</i>	14.90	0.1674	0.0001131	G	A	0.4205
19	rs4646515	15658569	<i>CYP4F3</i>	9.122	0.2503	0.002525	G	C	0.3636
X	rs2273081	4594630	<i>COL9A3</i>	12.17	0.1571	0.0004864	C	A	0.3429
22	rs229526	47236880	<i>C1QTNF6</i>	16.40	0.1324	0.00005141	G	A	0.3409
X	rs2980075	152794075	<i>ATP2B3</i>	11.62	0.1282	0.0006537	C	A	0.2286
21	rs373521	27257660	<i>APP</i>	12.5	0.1963	0.0004067	A	C	0.3864
6	rs1283468	70038147	<i>ADGRB3</i>	15.56	0.07051	0.00007978	A	G	0.1591
5	rs11956034	178754468	<i>ADAMTS2</i>	14.98	0.09502	0.0001088	A	G	0.1818
3	rs501118	95116949	-	15.66	8.7	0.000075922	A	G	0.375
21	rs9981074	33165958	-	13.54	6.29	0.0002341	A	G	0.4205

X	rs17317597	116660237	-	8.202	12.55	0.004185	G	A	0.2143
18	rs4347699	51183679	-	15.74	10.33	0.000072533	A	G	0.3409
X	rs12559502	128048545	-	6.893	0.2462	0.008651	G	A	0.3
X	rs17333434	27133302	-	8.072	0.2027	0.004495	G	A	0.2571
21	rs2829964	27242396	-	12.823	0.1914	0.0003425	A	G	0.4659
21	rs2142419	19928069	-	12.908	0.1778	0.0003272	A	G	0.3068
18	rs8082822	73209334	-	13.92	0.1769	0.0001909	A	G	0.375
X	rs6640653	4579981	-	9.714	0.1645	0.001829	A	C	0.2429
10	rs2068888	94839642	-	15.50	0.1603	0.0000827	G	A	0.4432
X	rs1343974	4594630	-	12.17	0.1571	0.0004864	C	A	0.3429
13	rs9548721	39846266	-	14.569	0.1546	0.0001351	G	A	0.2955
12	rs7135989	48655268	-	16.40	0.1324	0.000005141	A	G	0.2841
X	rs5916687	4596138	-	11.62	0.1282	0.0006537	A	G	0.2286
21	rs2829950	27223152	-	19.23	0.124	0.000011565	C	A	0.3636
X	rs5980684	69300000	-	13.57	0.1222	0.0002298	A	G	0.2714
6	rs1074349	22838984	-	18.63	0.1217	0.000015902	G	A	0.3182
22	rs134913	27413509	-	18.41	0.1111	0.000017857	G	A	0.2727
X	rs12390729	4597922	-	15.68	0.1053	0.00000055659	A	G	0.2857
13	rs944868	39843411	-	18.47	0.102	0.000017268	C	A	0.25
10	rs10787147	111079538	-	14.6	9.595	0.0001327	G	A	0.3295
14	rs2094718	99434288	-	13.5	8.908	0.000238	C	A	0.3182
X	rs1144863	144582143	-	12.83	7.986	0.0003411	A	G	0.4143
X	rs5915786	4642016	-	9.775	5.353	0.001769	G	A	0.4571

Table 05. Description of significant genes. Source: [69]

Gene	Brain Expression	Function
<i>SPPL2A</i>	+	Catalyzes the intramembrane cleavage of a several proteins and may play a role in the regulation of innate and adaptive immunity.
<i>APP</i>	+	Performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axogenesis.
<i>EXOSC7</i>	+	Presents exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events.
<i>GRID2</i>	+	Plays a role in synapse organization between parallel fibers and Purkinje cells.
<i>ADGRB3</i>	+	Plays a role in the regulation of synaptogenesis and dendritic spine formation.
<i>COL9A3</i>	+	Possesses the function of structural component of hyaline cartilage.
<i>LY9</i>	-	Modulates the activation and differentiation of a wide variety of immune cells and are involved in the regulation and interconnection of both innate and adaptive immune response.
<i>FOXN3</i>	+	Acts as a transcriptional repressor and may be involved in DNA damage-inducible cell cycle arrests (checkpoints).

Figure legends

Figure 01. Protein pathway network from STRING. Genes of positive SNPs with pharmacological targets. Colors of edges: black (co-expression), green (textmining), pink (experimentally determined) and blue (from curated databases). Colors of nodes: colored nodes – query proteins and first shell of interactors, white nodes – second shell of interactors. Node content: empty nodes – proteins of unknown 3D structure, filled nodes – some 3D structure is known or predicted.

Figure 02. Regulation of synaptic plasticity pathway.

In this way, the genes that are in bold and their hexagon-shaped nodules are the genes found after genome analysis through PLINK and Haploview. Ball-shaped nodules represent the pathways to which these genes participate. The interaction between the genes found results in the regulation pathway of synaptic plasticity.

The genes involved in this pathway are: *APP* (amyloid beta protein precursor), *SPPL2A* (GPCR signaling - transmembrane proteins), *EXOSC7* (exosome component), *FOXN3* (forkhead/winged helix transcription factor family), *GRID2* (glutamatergic ionotropic receptor), *LY9* (Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family), *ADGRB3* (brain-specific angiogenesis inhibitor), *COL9A3* (extracellular matrix structural constituent).

Figures




Figure 01. Protein pathway network from STRING.




Figure 02. Regulation of synaptic plasticity pathway.